HCA Healthcare profit guidance cut
Analysis based on 16 articles · First reported Jul 17, 2026 · Last updated Jul 30, 2026
HCA's stock dropped 6.95% on the guidance cut, reflecting investor concern over revenue pressure. The ongoing securities investigation may further weigh on the stock and increase legal costs.
HCA Healthcare, Inc. (NYSE: HCA) issued a press release on July 14, 2026, reporting preliminary Q2 2026 results and sharply lowering its full-year 2026 profit guidance due to an unfavorable shift in payer mix, impacting revenue by approximately $400 million. The stock price fell 6.95% ($27.14) to close at $363.60. Subsequently, Pomerantz LLP announced an investigation into whether HCA and certain officers/directors engaged in securities fraud or other unlawful business practices, urging investors to contact Danielle Peyton.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard